febuxostat has been researched along with concanavalin a in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (concanavalin a) | Trials (concanavalin a) | Recent Studies (post-2010) (concanavalin a) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 17,959 | 82 | 1,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelaziz, RR; Ibrahim, TM; Maresh, MM | 1 |
1 other study(ies) available for febuxostat and concanavalin a
| Article | Year |
|---|---|
Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1β, TNF-α, neutrophil infiltration, and apoptosis in mice.
Topics: Animals; Apoptosis; Caspase 3; Chemokine CCL2; Concanavalin A; Febuxostat; Hepatitis; Interleukin-1beta; Liver; Male; Mice; Neutrophil Infiltration; Neutrophils; Peroxidase; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |